Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.

Diabetes Metab Syndr · 2021 · PMC7832723 · PMID 33352455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

[ 30 ] that analyzed the outcome with metformin in patients with non-alcoholic fatty liver disease (NAFLD) or steato-hepatitis (NASH) with COVID-19 without diabetes, has also shown a reduced risk of hospital admission in metformin users (36/6700) (OR 0.42; 95% CI, 0.18–1.01; p = 0.05) compared to the non-users, although it was nominally significant.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.